MedPath

PRIORIX

PRIORIX

Approved
DIN Number

02239208

Drug Class

Human

Market Date

Dec 4, 1998

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02239208
AIG Number0431514004
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07BD52 MEASLES, COMBIN. WITH MUMPS AND RUBELLA, LIVE ATTENUATED
Product Specifications
Dosage FormKit ,  Powder For Solution
Route of AdministrationIntramuscular ,  Subcutaneous
AHFS Classification80:12.00
Health Canada Classification

ACTIVE INGREDIENTS (4)

MEASLES VIRUS VACCINE LIVE ATTENUATEDActive
Strength: 1000 CCID50 / 0.5 ML
Monograph: MEASLES VIRUS VACCINE LIVE ATTENUATED
MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN)Active
Strength: 10000 CCID50 / 0.5 ML
Monograph: MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN)
RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN)Active
Strength: 1000 CCID50 / 0.5 ML
Monograph: RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN)
WATERActive
Strength: 0.5 ML
Monograph: WATER

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.